Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD) (ARISE)
This study has been completed.
Sponsor:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01285492
First received: January 25, 2011
Last updated: November 2, 2012
Last verified: November 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a 52-week treatment, multi-center, randomized, open label, parallel group study to assess the long term safety and tolerability of once-daily QVA149 (indacaterol and NVA237 (glycopyrronium bromide) using tiotropium as an active control in Japanese patients with moderate to severe chronic obstructive pulmonary disease (COPD).
| Condition | Intervention | Phase |
|---|---|---|
|
Chronic Obstructive Pulmonary Disease (COPD) |
Drug: QVA149 Drug: Tiotropium |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD) |
Resource links provided by NLM:
MedlinePlus related topics:
COPD (Chronic Obstructive Pulmonary Disease)
Drug Information available for:
Tiotropium bromide
U.S. FDA Resources
Further study details as provided by Novartis:
Primary Outcome Measures:
- Safety and tolerability of QVA149 with regard to treatment-emergent adverse events [ Time Frame: 52 weeks ] [ Designated as safety issue: Yes ]treatment-emergent adverse events
Secondary Outcome Measures:
- Safety of QVA149 as compared with tiotropium with regard to vital signs, electrocardiogram (ECG), and laboratory measurements [ Time Frame: 52 weeks ] [ Designated as safety issue: Yes ]vital signs (blood pressure, pulse rate), ECG, laboratory measurements (hematology, urinalysis, clinical chemistry)
- To assess the safety of QVA149 as compared with tiotropium with regard to study drug discontinuation [ Time Frame: 52 weeks ] [ Designated as safety issue: Yes ]Measure: study drug discontinuation
| Enrollment: | 160 |
| Study Start Date: | January 2011 |
| Study Completion Date: | September 2012 |
| Primary Completion Date: | September 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: QVA149
QVA149 delivered once daily via a single-dose dry powder inhaler (SDDPI)
|
Drug: QVA149 |
|
Active Comparator: Tiotropium
Tiotropium delivered once-daily via HandiHaler
|
Drug: Tiotropium |
Eligibility| Ages Eligible for Study: | 40 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients with moderate to severe stable COPD (Stage II or Stage III) according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines 2008.
- Current or ex-smokers who have a smoking history of at least 10 pack years. (Ten pack years are defined as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20 years etc.)
- Patients with post-bronchodilator forced expiratory volume in one second (FEV1) ≥30% and < 80% of the predicted normal, and post-bronchodilator FEV1/forced vital capacity (FVC) < 0.7 at Visit 2.
Exclusion Criteria:
- Pregnant women or nursing mothers or women of child-bearing potential not using an acceptable method of contraception
- Patients requiring long term oxygen therapy
- Patients who have had a lower respiratory tract infection within 4 weeks prior to Visit 1
- Patients with concomitant pulmonary disease
- Patients with a history of asthma
- Any patient with history of malignancy of any organ system (including lung cancer), treated or untreated, within the past 5 years
- Patients with a history of certain cardiovascular comorbid conditions
- Patients with a known history and diagnosis of alpha-1 antitrypsin deficiency
- Patients in the active phase of a supervised pulmonary rehabilitation program
- Patients contraindicated for treatment with, or having a history of reactions/ hypersensitivity to anticholinergic agents, long and short acting beta-2 agonists, sympathomimetic amines
Other protocol-defined inclusion/exclusion criteria may apply
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01285492
Locations
| Japan | |
| Novartis Investigative Site | |
| Anjo, Aichi, Japan, 446-8602 | |
| Novartis Investigative Site | |
| Nagoya, Aichi, Japan, 457-8511 | |
| Novartis Investigative Site | |
| Nishio-city, Aichi, Japan, 445-8510 | |
| Novartis Investigative Site | |
| Kasuga-city, Fukuoka, Japan, 816-0813 | |
| Novartis Investigative Site | |
| Kitakyushu, Fukuoka, Japan, 820-0052 | |
| Novartis Investigative Site | |
| Kurume, Fukuoka, Japan, 830-0011 | |
| Novartis Investigative Site | |
| Yanagawa, Fukuoka, Japan, 832-0059 | |
| Novartis Investigative Site | |
| Asahikawa, Hokkaido, Japan, 070-8644 | |
| Novartis Investigative Site | |
| Obihiro, Hokkaido, Japan, 080-0805 | |
| Novartis Investigative Site | |
| Sapporo, Hokkaido, Japan, 060-8648 | |
| Novartis Investigative Site | |
| Himeji-city, Hyogo, Japan, 672-8064 | |
| Novartis Investigative Site | |
| Kanazawa, Ishikawa, Japan, 920-8610 | |
| Novartis Investigative Site | |
| Takamatsu, Kagawa, Japan, Japan | |
| Novartis Investigative Site | |
| Kawasaki, Kanagawa, Japan, 210-0852 | |
| Novartis Investigative Site | |
| Yokohama, Kanagawa, Japan, 236-0051 | |
| Novartis Investigative Site | |
| Goshi, Kumamoto, Japan, 861-1196 | |
| Novartis Investigative Site | |
| Matsusaka-city, Mie, Japan, 515-8544 | |
| Novartis Investigative Site | |
| Ueda, Nagano, Japan, 386-8610 | |
| Novartis Investigative Site | |
| Osakasayama, Osaka, Japan, 589-0022 | |
| Novartis Investigative Site | |
| Takatsuki, Osaka, Japan, 569-1192 | |
| Novartis Investigative Site | |
| Toyonaka, Osaka, Japan, 560-8552 | |
| Novartis Investigative Site | |
| Kawaguchi, Saitama, Japan, 333-0833 | |
| Novartis Investigative Site | |
| Hamamatsu, Shizuoka, Japan, 430-8525 | |
| Novartis Investigative Site | |
| Fuchu, Tokyo, Japan, 183-8524 | |
| Novartis Investigative Site | |
| Meguro, Tokyo, Japan, 152-8902 | |
| Novartis Investigative Site | |
| Yamagata city, Yamagata, Japan, 990-8533 | |
| Novartis Investigative Site | |
| Ube, Yamaguchi, Japan, 755-0241 | |
| Novartis Investigative Site | |
| Akita, Japan, 010-0933 | |
| Novartis Investigative Site | |
| Fukuoka, Japan, 811-0213 | |
| Novartis Investigative Site | |
| Fukuoka, Japan, 812-0033 | |
| Novartis Investigative Site | |
| Fukuoka, Japan, 815-8588 | |
| Novartis Investigative Site | |
| Kochi, Japan, 780-8077 | |
| Novartis Investigative Site | |
| Osaka, Japan, 545-8586 | |
| Novartis Investigative Site | |
| Osaka, Japan, 558-8558 | |
| Novartis Investigative Site | |
| Wakayama, Japan, 641-8510 | |
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
| Study Director: | Novartis Pharmaceuticals | Novartis Pharmaceuticals |
More Information
No publications provided
| Responsible Party: | Novartis ( Novartis Pharmaceuticals ) |
| ClinicalTrials.gov Identifier: | NCT01285492 History of Changes |
| Other Study ID Numbers: | CQVA149A1301 |
| Study First Received: | January 25, 2011 |
| Last Updated: | November 2, 2012 |
| Health Authority: | United States: Food and Drug Administration Japan: Ministry of Health, Labor and Welfare |
Keywords provided by Novartis:
|
COPD QVA149 NVA237 indacaterol combination bronchodilator |
Additional relevant MeSH terms:
|
Lung Diseases Respiration Disorders Pulmonary Disease, Chronic Obstructive Lung Diseases, Obstructive Respiratory Tract Diseases Tiotropium Parasympatholytics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs |
Pharmacologic Actions Cholinergic Antagonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Bronchodilator Agents Anti-Asthmatic Agents Respiratory System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 23, 2013